Trulieve Cannabis (NYSE:TRLV) Coverage Initiated at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald assumed coverage on shares of Trulieve Cannabis (NYSE:TRLV) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $15.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 70.69% from the company’s previous close.

A number of other equities analysts have also recently commented on TRLV. Weiss Ratings initiated coverage on shares of Trulieve Cannabis in a research report on Tuesday, June 16th. They issued a “sell (d-)” rating on the stock. Wall Street Zen cut Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Zacks Research upgraded Trulieve Cannabis to a “hold” rating in a report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $15.00.

Trulieve Cannabis Stock Down 0.0%

Shares of TRLV opened at $8.79 on Monday. Trulieve Cannabis has a fifty-two week low of $4.00 and a fifty-two week high of $13.28.

Insider Activity

In other news, CEO Kim A. Rivers sold 400,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $8.17, for a total value of $3,268,000.00. Following the transaction, the chief executive officer owned 1,913,724 shares in the company, valued at approximately $15,635,125.08. This trade represents a 17.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,699,007 shares of company stock valued at $14,661,355 in the last quarter. 3.79% of the stock is currently owned by company insiders.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.